Gil Morgan MD

YouTube video by OncoAlert 360 The TOP News THIS WEEK in Oncology July 4-10, 2025 : OncoAlert Weekly Round Up with Dr. Gil Morgan

The OncoAlert🚨Weekly Round Up Covering July 4-10, 2025
www.youtube.com/watch?v=ib45...
👉 REGISTER at www.OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoa...

The #ASCO25 #OncoAlertTOP10 Abstracts in #LungCancer 🫁 These are some of our picks of TOP abstracts we look forward to be presented at the upcoming ASCO Meeting in Chicago 🇺🇸

@biagioricciutimd.bsky.social
‬ @stephenvliu.bsky.social
@drsanjaypopat.bsky.social
Ping
@drjnaidoo.bsky.social

The #ASCO25 #OncoAlertTOP10 Abstracts in GI Oncology
These are some of our picks of TOP abstracts we look forward to be presented at the upcoming ASCO Meeting in Chicago🇺🇸

@realbowtiedoc.bsky.social‬
@arosen380.bsky.social‬
Ping
‪@gillsharlene.bsky.social‬

Love the just in time education provided in the @oncoalert.bsky.social weekly roundup to keep me informed of the latest in cancer research!
TY @weoncologists.bsky.social !
#oncologynursing

The time is now! ⏰

Follow along for the best of #ASCO25

Top 10 trials in #GIonc and #pallonc are incoming 🔮

@oncoalert.bsky.social
@weoncologists.bsky.social
@pallonccop.bsky.social
@biagioricciutimd.bsky.social
@drnataliagandur.bsky.social
@elisabettabonzano.bsky.social
@kjankovic.bsky.social

YouTube video by OncoAlert 360 The OncoAlert Oncology Round Up May 15-22, 2025 Top Oncology Breakthroughs in less than 5 Min!

The OncoAlert🚨ROUND UP Now Out‼️
Covering May 15-22, 2025

REGISTER at oncoalert360.com OR oncoalert.m-pages.com/nhMpwe/oncoa...

youtu.be/xgIw0BISCpo

@elisaagostinetto.bsky.social
@barbaramelao.bsky.social
@elisaagostinetto.bsky.social
@icromeattini.bsky.social
@realbowtiedoc.bsky.social

Zanidatamab plus palbociclib and fulvestrant in previously treated patients with hormone receptor-positive, HER2-positive metastatic breast cancer: primary results from a two-part, multicentre, single... Zanidatamab plus palbociclib and fulvestrant was generally safe and showed promising antitumour activity, supporting further evaluation of this chemotherapy-free triplet regimen.

Zanidatamab plus palbociclib and fulvestrant in previously treated patients with HR+, HER2+ metastatic #BreastCancer

www.thelancet.com/journals/lan...

Results support further investigation of this chemotherapy-free triplet approach as a potential tx option

@erikahamilton9.bsky.social

The Role of Prostate-specific Membrane Antigen Positron Emission Tomography for Assessment of Local Recurrence and Distant Metastases in Patients with Biochemical Recurrence of Prostate Cancer After D... Positron emission tomography (PET) with prostate-specific membrane antigen (PSMA) radioligands has an established role in the assessment of recurrence…

Role of Prostate-specific Membrane Antigen Positron Emission Tomography for Assessment of Local Recurrence & Distant Metastases in Biochemical Recurrence of #ProstateCancer After Definitive Treatment

www.sciencedirect.com/science/arti...

Findings underscore importance of PSA stratification

Characteristics of Patients and Prognostic Factors Across Treatment Lines in Metastatic Colorectal Cancer

ascopubs.org/doi/full/10....

analyzed individual data from 48 randomized trials in metastatic #ColorectalCancer to understand how tumor characteristics evolve across treatment lines

You're invited to join the Post-ASCO 2025 Breast Cancer Highlights webinar, hosted by VJOncology. Featuring expert presentations and in-depth discussions on key abstracts in #BreastCancer presented at ASCO 2025.

Register Here 👉 us06web.zoom.us/webinar/regi...

June 17, 2025
16:00–18:00 CEST

out on Lancet Oncology by Blondeaux🇮🇹 & Lambertini 🇮🇹et al🌐https://thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00152-4/abstractIn a large int... Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer

The @OncoAlert 🚨 @VJOncology JOURNAL CLUB
Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: an international cohort study out on Lancet Oncology by Blondeaux🇮🇹 & Lambertini 🇮🇹et al🌐

thelancet.com/journals/lan...

youtu.be/z-BRKbIUco0

Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, double-blind, phase III KEYNOTE-991 study Despite treatment advances, most patients with metastatic hormone-sensitive prostate cancer (mHSPC) experience disease progression to castration-resistant disease within 5 years. The placebo-controlled, double-blind, phase III KEYNOTE-991 study evaluated the efficacy and safety of adding pembrolizumab to enzalutamide and androgen deprivation therapy (ADT) in participants with mHSPC.

Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive #ProstateCancer : the randomized, double-blind, phase III KEYNOTE-991 study

annalsofoncology.org/article/S092...

Advancing breast cancer treatment in the era of molecular diagnostics Advances in cancer biology and drug development now enable treatments tailored to individual tumor profile. Targeting specific molecular alterations, marking a significant step forward in cancer care,...

Advancing breast cancer treatment in the era of molecular diagnostics

thebreastonline.com/article/S096...

Recent advances in #BreastCancer treatment have shifted toward personalized, biomarker-driven approaches that leverage molecular diagnostics to guide therapy selection. ]

Emerging Role of Targeted Therapies Combined with Radiotherapy in Inoperable Stage I-III, Non-Small Cell Lung Cancer (NSCLC): A Review from the International Association for the Study of Lung Cancer (IASLC) Advanced Radiation Technology (ART) Subcommittee.

www.jto.org/article/S155...

YouTube video by OncoAlert 360 Oncology Here & Now: GU Oncology With Dr. Melão & Dr. Spiess (Upper Tract Urothelial Carcinoma)

Oncology Here & Now Pod/Web Cast🚨

Join Urology colleagues, Dr. @barbaramelao.bsky.social 🇧🇷and Dr. Philippe Spiess🇺🇸, as they discuss upper tract urothelial carcinoma—from risk stratification to management strategies in both low-risk and high-risk, high-grade settings.

youtu.be/pfkLTzWX4AU

Emerging Role of Targeted Therapies Combined with Radiotherapy in Inoperable Stage I-III, Non-Small Cell Lung Cancer (NSCLC)
www.jto.org/article/S155...

The review also examines the incidence of actionable mutations, toxicity considerations, sequencing strategies, and ongoing trials

Bring Your Research Ideas to Life — Meet with MEDSIR at #ASCO25 to Get Started!

👉 www.medsir.org/events/asco2...

MEDSIR is a global oncology research company that designs and runs innovative, patient-focused clinical trials through agile, independent collaborations with investigators & industry

NEWS FROM INDUSTRY: SOURCE MERCK
KEYNOTE-B96 Update #OvarianCancer

KEYNOTE-B96 (ENGOT-ov65) trial sees pembrolizumab combined with chemotherapy , w/ or w/o bevacizumab, improved PFS in patients w/ platinum-resistant recurrent #OvarianCancer regardless of PD-L1

www.merck.com/news/merck-a...

You are warmly invited to watch the Top Trials of the Year🚨 presented by some of the world’s leading experts. All sessions are free and available on demand
NO REGISTRATION NEEDED, JUST CLICK AND WATCH

⭐ GU Oncology
buff.ly/3hkYYG6

⭐ #BreastCancer
buff.ly/EH7RPPc

Dr. Evandro de Azambuja discusses the final analysis of the APHINITY Breast Cancer trial just presented at ESMO Breast 2025. VJ OA Oncology Journal Club: Final Results of the APHINITY Breast Cancer Trial Presented at ESMO ...

The @OncoAlert 🚨 @VJOncology JOURNAL CLUB
Today we present @E_de_Azambuja 🇧🇪of @JulesBordet who talks to us about the Final Analysis of the APHINITY trial just Presented at #ESMOBreast25
youtu.be/ydcXe_faQH0

A sub analysis was just published out on European Journal of Cancer:

Duration and effect of neoadjuvant endocrine therapy on invasive tumor cellularity in hormone receptor-positive breast cancer - Breast Cancer Research and Treatment Purpose Neoadjuvant chemotherapy has been used to evaluate tumor response and downstage hormone sensitive localized breast cancers. However, complete pathological responses are uncommon. Neoadjuvant e...

Duration and effect of neoadjuvant endocrine therapy on invasive tumor cellularity in hormone receptor-positive #BreastCancer

link.springer.com/article/10.1...

Findings suggest that prolonged NET may lead to more substantial tumor downstaging

Patient-Reported Outcomes With Stereotactic Intensity Modulated Radiotherapy After Radical Prostatectomy This nonrandomized clinical trial evaluates physician-reported late toxic effects and 2-year patient-reported outcomes following post–radical prostatectomy stereotactic body radiotherapy.

Patient-Reported Outcomes With Stereotactic Intensity Modulated Radiotherapy After Radical Prostatectomy

jamanetwork.com/journals/jam...

findings suggest that post-RP SBRT is a well-tolerated alternative to Conventionally Fractionated RT
#ProstateCancer

@silkegillessen.bsky.social 🚨

Oral Ketamine as an Analgesic Therapy: Systematic Review of Randomised Clinical Trials Ketamine is an analgesic used to manage neuropathic pain, but its use is limited by side effects and intravenous administration. Recently, the use of oral and nasal administration has expanded. How...

#Pallonc review on oral #ketamine use

6 #RCT mixed evidence ⚖️
Some ⬇️ refractory #pain
Results varied and #tox common 😵‍💫🥴
⬆️ trials 📊needed to guide outpatient use
#hpm #hapc

🔗: tandfonline.com/doi/full/10....

@oncoalert.bsky.social
@weoncologists.bsky.social
@pallonccop.bsky.social

PRODIGE 29-UCGI 26 (NEOPAN): A Phase III Randomized Trial Comparing Chemotherapy With FOLFIRINOX or Gemcitabine in Locally Advanced Pancreatic Carcinoma PURPOSEMore than 30% of patients with pancreatic cancer are unresectable because of the local extension with a median overall survival (OS) of <1 year. Combination of fluorouracil (FU), oxaliplatin...

PRODIGE 29-UCGI 26 (NEOPAN) Comparing Chemotherapy W/ FOLFIRINOX or Gemcitabine in Locally Advanced #PancreaticCarcinoma

ascopubs.org/doi/abs/10.1...

FOLFIRINOX significantly improved PFS compared to gemcitabine, though OS was similar between the two treatments

ping @realbowtiedoc.bsky.social

Looking forward to seeing the data for neoadjuvant T-DXd ➡️ THP in patients with high risk, locally advanced HER2+ breast cancer! 💉
Rates of ILD similar among T-DXd/THP vs ddAC-THP arms🫁

Updated Prostate Cancer Risk Groups by Prostate-specific Membrane Antigen Positron Emission Tomography Prostate Cancer Molecular Imaging Standardized Evaluation (PPP2): Results from an International M... We established prognostic nomograms incorporating prostate-specific membrane antigen (PSMA) positron emission tomography (PET) parameters standardised…

Updated Prostate Cancer Risk Groups by Prostate-specific Membrane Antigen Positron Emission Tomography #ProstateCancer Molecular Imaging Standardized Evaluation (PPP2)

www.sciencedirect.com/science/arti...

PPP2 offers a robust tool for 3- and 5-year survival prediction

NEWS FROM INDUSTRY

Astra Zeneca reports that the POTOMAC Phase III trial demonstrated that adding 1yr durvalumab to standard Bacillus Calmette-Guérin induction and maintenance therapy significantly improved DGS in high-risk non-muscle-invasive #BladderCancer
www.astrazeneca.com/media-centre...

Atezolizumab plus personalized neoantigen vaccination in urothelial cancer: a phase 1 trial - Nature Cancer Galsky and colleagues report the results of a phase 1 clinical trial of anti-programmed cell death protein 1 ligand 1 atezolizumab in combination with PGV001, a personalized neoantigen vaccine, in par...

Atezolizumab plus personalized neoantigen vaccination in urothelial cancer: a phase 1 trial OUT ON nature Cancer

www.nature.com/articles/s43...

Trial met its primary endpoints, supporting the feasibility and safety of this approach, and suggesting it warrants further investigation. #BladderCancer

The OncoAlert🚨Newsletter Now Out Covering May 2-8, 2025

REGISTER at www.OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoa...

✅DESTINY-Breast11 Update from Industry
✅PEACE V STORM in #Prostate Cancer⛈️🕊️☢️
✅OS🧬EGFR-mutant Advanced🫁Non-Small Cell #LungCancer Treated with 1L Osimertinib
and more

NEWS FROM INDUSTRY🚨 Source AstraZeneca
DESTINY-Breast11 Update

DESTINY-Breast11 sees trastuzumab deruxtecan followed by paclitaxel, trastuzumab, and pertuzumab improved pathologic complete response rates compared to the standard neoadjuvant regimen

www.astrazeneca.com/media-centre...